These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34814882)

  • 1. Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis.
    Kharel S; Shrestha S; Ojha R; Guragain N; Ghimire R
    BMC Neurol; 2021 Nov; 21(1):458. PubMed ID: 34814882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders.
    Xie Q; Zheng T; Sun M; Sun J; Wang M
    Mult Scler Relat Disord; 2020 Oct; 45():102421. PubMed ID: 32731203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.
    Lotan I; McGowan R; Levy M
    Curr Neuropharmacol; 2021; 19(2):220-232. PubMed ID: 32348222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
    Ringelstein M; Ayzenberg I; Harmel J; Lauenstein AS; Lensch E; Stögbauer F; Hellwig K; Ellrichmann G; Stettner M; Chan A; Hartung HP; Kieseier B; Gold R; Aktas O; Kleiter I
    JAMA Neurol; 2015 Jul; 72(7):756-63. PubMed ID: 25985228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
    J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
    Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
    Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety.
    Wang Y; Zhao M; Yao M; Yang Z; Li B; Yin L; Geng X
    Mult Scler Relat Disord; 2023 Dec; 80():105062. PubMed ID: 37866020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
    Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K
    Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.
    Du C; Zeng P; Han JR; Zhang TX; Jia D; Shi FD; Zhang C
    Front Immunol; 2021; 12():660230. PubMed ID: 34745082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials.
    Xue T; Yu J; Chen S; Wang Z; Yang Y; Chen Z; Wang Z
    Front Neurol; 2020; 11():604445. PubMed ID: 33391166
    [No Abstract]   [Full Text] [Related]  

  • 16. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
    Rosso M; Saxena S; Chitnis T
    Expert Rev Neurother; 2020 May; 20(5):509-516. PubMed ID: 32306778
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.
    Araki M; Matsuoka T; Miyamoto K; Kusunoki S; Okamoto T; Murata M; Miyake S; Aranami T; Yamamura T
    Neurology; 2014 Apr; 82(15):1302-6. PubMed ID: 24634453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.